| Description | Inarigivir ammonium (SB-9200 ammonium) is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity. |
| In vitro | Inarigivir 对携带所有已批准用于治疗慢性乙型肝炎的核苷(酸)类似物抗性标志的 HBV 变种具有活性[1]。 |
| In vivo | 给予每日100 mg/kg Inarigivir（ip）显著降低肝脏中的病毒DNA，并显示出对HBV的抗病毒活性，而血清HBV DNA的水平未见下降。Inarigivir对肝脏中HBV RNA的水平、血清中HBeAg的水平或HBsAg的平均滴度无影响。通过使用肝脏HBV DNA的值[2]，确定最小有效剂量介于1.6至0.5 mg/kg/日之间。 |
| Synonyms | ORI-9020 ammonium, SB-9200 ammonium, Inarigivir铵 |
| molecular weight | 604.53 |
| Molecular formula | C20H29N8O10PS |
| CAS | 2172788-92-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 98 mg/mL (162.11 mM) |
| References | 1. Danni Colledge, et al. The Novel Antiviral Agent Inarigivir Inhibits Both Nucleos(t)ide Analogue and Capsid Assembly Inhibitor Resistant HBV in vitro. 2. Iyer RP, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48(6):2318-20. |